Literature DB >> 23455599

Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash.

F L Wright1, R J Rodgers.   

Abstract

RATIONALE: In appetite research, drugs frequently progress to clinical trials on the basis of outcome (reduced food intake/body weight gain) with insufficient attention to process (behavioural analysis). Although bupropion and naltrexone (alone and in combination) reduce food consumption in rodents and humans, their effects on behaviour during feeding tests have not been thoroughly investigated.
OBJECTIVES: This study aimed to assess the behavioural specificity of anorectic responses to bupropion, naltrexone and their combination.
METHODS: Video analysis was employed to characterise the behavioural effects of acute systemic treatment with bupropion (10.0-40.0 mg/kg), naltrexone (0.1-3.0 mg/kg) and combined bupropion (20 mg/kg) plus naltrexone (0.1-1.0 mg/kg) in non-deprived male rats exposed for 1 h to palatable mash. Particular attention was paid to the behavioural satiety sequence (BSS).
RESULTS: In experiment 1, the anorectic response to 40 mg/kg bupropion was associated with significant psychomotor stimulation and a complete disruption of the BSS. In experiment 2, the anorectic response to 3 mg/kg naltrexone was associated with an accelerated but otherwise normal BSS. In experiment 3, the co-administration of 20 mg/kg bupropion and naltrexone (0.1 and 1.0 mg/kg) not only produced an additive anorectic profile (including a reduced rate of eating), but the addition of the opioid receptor antagonist also concurrently attenuated the psychomotor stimulant response to the atypical antidepressant.
CONCLUSIONS: Low-dose co-treatment with naltrexone and bupropion produces a stronger suppression of appetite than that seen with either agent alone and has the additional advantage of reducing some of the unwanted effects of bupropion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23455599     DOI: 10.1007/s00213-013-3036-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  81 in total

Review 1.  Animal models to explore the effects of CNS drugs on food intake and energy expenditure.

Authors:  Steven P Vickers; Peter G Clifton
Journal:  Neuropharmacology       Date:  2012-04-10       Impact factor: 5.250

2.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

3.  Behavioral effects of separate and combined administration of naloxone and d-amphetamine.

Authors:  S G Holtzman
Journal:  J Pharmacol Exp Ther       Date:  1974-04       Impact factor: 4.030

4.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

5.  15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.

Authors:  Maurizio Fava; A John Rush; Michael E Thase; Anita Clayton; Stephen M Stahl; James F Pradko; J Andrew Johnston
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

6.  Cocaine: a microstructural analysis of its effects on feeding and associated behaviour in the rat.

Authors:  S J Cooper; G A van der Hoek
Journal:  Brain Res       Date:  1993-04-09       Impact factor: 3.252

7.  Opioid receptor involvement in food deprivation-induced feeding: evaluation of selective antagonist and antisense oligodeoxynucleotide probe effects in mice and rats.

Authors:  M M Hadjimarkou; A Singh; Y Kandov; Y Israel; Y-X Pan; G C Rossi; G W Pasternak; R J Bodnar
Journal:  J Pharmacol Exp Ther       Date:  2004-08-27       Impact factor: 4.030

8.  Rational design of a combination medication for the treatment of obesity.

Authors:  Frank L Greenway; M J Whitehouse; Maria Guttadauria; James W Anderson; Richard L Atkinson; Ken Fujioka; Kishore M Gadde; Alok K Gupta; Patrick O'Neil; Donald Schumacher; Diane Smith; Eduardo Dunayevich; Gary D Tollefson; Eckard Weber; Michael A Cowley
Journal:  Obesity (Silver Spring)       Date:  2008-11-06       Impact factor: 5.002

9.  Effects of bupropion, alone or coadministered with nicotine, on social behavior in mice.

Authors:  Carmen Gómez; Carmen Carrasco; Rosa Redolat
Journal:  Addict Biol       Date:  2008-03-07       Impact factor: 4.280

10.  Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis.

Authors:  Sonja K Billes; Michael A Cowley
Journal:  Neuropsychopharmacology       Date:  2007-08-08       Impact factor: 7.853

View more
  8 in total

1.  Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2014-02-28       Impact factor: 4.530

2.  On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2013-10-11       Impact factor: 4.530

Review 3.  Neural control of energy balance: translating circuits to therapies.

Authors:  Laurent Gautron; Joel K Elmquist; Kevin W Williams
Journal:  Cell       Date:  2015-03-26       Impact factor: 41.582

4.  Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats.

Authors:  Emily R Nicholson; Julian E Dilley; Janice C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  2018-01-22       Impact factor: 3.455

5.  Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice.

Authors:  Yan Zhou; Francesco Leri; Malcolm J Low; Mary Jeanne Kreek
Journal:  Pharmacol Biochem Behav       Date:  2019-04-13       Impact factor: 3.533

6.  Involvement of Endogenous Enkephalins and β-Endorphin in Feeding and Diet-Induced Obesity.

Authors:  Ian A Mendez; Sean B Ostlund; Nigel T Maidment; Niall P Murphy
Journal:  Neuropsychopharmacology       Date:  2015-03-10       Impact factor: 7.853

7.  A Preliminary, Open-Label Study of Naltrexone and Bupropion Combination Therapy for Treating Binge Drinking in Human Subjects.

Authors:  T Jordan Walter; Montserrat Navarro; Todd E Thiele; Cort Pedersen; Alexey Kampov-Polevoy; J C Garbutt
Journal:  Alcohol Alcohol       Date:  2020-02-07       Impact factor: 3.913

8.  Chronic Intermittent Sucrose Consumption Facilitates the Ability to Discriminate Opioid Receptor Blockade with Naltrexone in Rats.

Authors:  David C Jewett; Donisha S N K Liyanagamage; Mark A Vanden Avond; Molly A B Anderson; Kyleigh A Twaroski; Morgan A Marek; Kimberly F James; Tapasya Pal; Anica Klockars; Pawel K Olszewski; Allen S Levine
Journal:  Nutrients       Date:  2022-02-22       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.